G1 Therapeutics Inc represents values of innovation, dedication, and patient-centered care. Their corporate philosophy revolves around the development of novel therapies to address the unmet needs of patients with cancer. As a biopharmaceutical company, G1 Therapeutics is committed to improving outcomes and quality of life for individuals battling cancer. Their focus on precision medicine and understanding the biology of cancer has led to the creation of potential breakthrough therapies. G1 Therapeutics Inc strives to make a positive impact in the lives of patients worldwide by relentlessly pursuing innovative approaches to cancer treatment.

G1 Therapeutics Inc is primarily present in the United States.

G1 Therapeutics Inc, a renowned biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the FDA approval of their key drug, trilaciclib, as a treatment for small cell lung cancer (SCLC). Additionally, G1 Therapeutics Inc successfully completed a Phase 2 clinical trial demonstrating positive results for trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). The company also entered into partnerships with leading organizations, such as Boehringer Ingelheim, for the global development and commercialization of their investigational oral selective estrogen receptor degrader (SERD) in breast cancer. These achievements solidify G1 Therapeutics Inc as a promising player in the field of oncology therapeutics.

G1 Therapeutics Inc is a pharmaceutical company specializing in the development of novel therapies for patients with cancer. Founded in 2008, G1 Therapeutics is focused on advancing their pipeline of small molecule therapies that target key pathways involved in cell cycle progression and DNA damage repair. The company has garnered attention for its innovative approach to cancer treatment, utilizing precision medicine and targeted therapies. G1 Therapeutics' dedication to improving the lives of cancer patients has propelled its growth and success in the biopharmaceutical industry. With a strong focus on clinical development and strategic partnerships, G1 Therapeutics continues to pave the way for advancements in oncology therapeutics.

The main competitors of G1 Therapeutics Inc in the market include pharmaceutical companies such as Bristol-Myers Squibb, Merck & Co., and Pfizer Inc.

G1 Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of G1 Therapeutics Inc focuses on the development and commercialization of novel therapies for the treatment of cancer. The company aims to address the unmet needs of patients by advancing its pipeline of potential therapies that target specific cellular pathways involved in tumor growth. G1 Therapeutics Inc leverages its expertise in cell cycle biology and deep understanding of cancer biology to develop innovative drugs, with a particular focus on targeting metastatic breast cancer and small cell lung cancer. Through strategic partnerships and collaborations, G1 Therapeutics Inc aims to bring its potential breakthrough therapies to market, improving the lives of cancer patients worldwide.

G1 Therapeutics KGV ir -16,66.

G1 Therapeutics KUV ir 4,93.

AlleAktien kvalitātes vērtējums G1 Therapeutics ir 2/10.

gaidāmā G1 Therapeutics apgrozījums ir 75,01 milj. USD.

gaidāmā G1 Therapeutics peļņa ir -22,20 milj. USD.

G1 Therapeutics is a biopharmaceutical company specializing in the development of groundbreaking cancer drugs to improve the lives of patients suffering from various forms of cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics' business model is based on the development and marketing of drugs targeting specific target proteins found in cancer cells. By targeting these proteins, the company effectively inhibits the proliferation and spread of cancer cells. In addition, the company also provides services in the areas of research and development and clinical trials to ensure that the effectiveness and safety of its drugs are of the highest level. The company has developed several product lines targeting different types of cancer. Primarily, this includes innovative therapeutics for the treatment of advanced stage cancers, particularly advanced lung cancer and breast cancer. The company's flagship product is Rintodestrant (G1T48), an orally administered selective estrogen receptor modulator (SERM) currently being investigated in phase 2b clinical trials for the treatment of ER-positive (ER+) breast cancer. Rintodestrant offers an alternative treatment profile for patients receiving anti-hormone therapies, improving their quality of life by minimizing undesirable effects such as hot flashes, bleeding, and cardiovascular diseases. The company has also developed a drug candidate called Trilaciclib (G1T28), which is used as the first and only myelosuppression-reducing drug to protect bone marrow associated with chemotherapy. Trilaciclib should be used in situations where significant myelosuppressive chemotherapy is anticipated. Alongside chemotherapy, it may help reduce the toxic effects on bone marrow function, especially hematopoietic stem cells. With the introduction of additional monoclonal antibodies and immunotherapy variants, the company aims to expand its presence in the field of cancer treatment and expand its portfolio of drugs manufactured on an improved medical basis. In addition to its own product development, G1 Therapeutics works closely with partners in the science and industry sectors to expand its knowledge and capabilities in the field of cancer research and development. Overall, G1 Therapeutics pursues an innovative business model and positions itself as a key partner in cancer research and development. Through the constant development of new drugs and services, the company contributes to improving healthcare and ensuring that patients can be effectively treated against cancer.

G1 Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt G1 Therapeutics vai uzņēmums nedod dividendes.

G1 Therapeutics ISIN ir US3621LQ1099.

G1 Therapeutics WKN ir A2DR0J.

G1 Therapeutics simbols ir GTHX.

Pēdējo 12 mēnešu laikā G1 Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos G1 Therapeutics plāno maksāt dividendes 0 USD apmērā.

G1 Therapeutics pašreizējā dividendu rentabilitāte ir .

G1 Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

G1 Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

G1 Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu G1 Therapeutics apmērā 0 USD, kas tika izmaksāta 14.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 14.11.2024..

Pēdējās dividendes izmaksa notika 14.11.2024..

Gadā 2023, G1 Therapeutics izmaksāja 0 USD dividendes.

G1 Therapeutics dividendes tiek izmaksātas USD.